CA
VKTX icon

CoreCap Advisors’s Viking Therapeutics VKTX Stock Holding History

CoreCap Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98K Hold
102
– – ﹤0.01% 2346
2026
Q1 		$3.32K Buy
102
+50
+96% +$1.61K ﹤0.01% 2290
2025
Q4 		$1.83K Hold
52
– – ﹤0.01% 2494
2025
Q3 		$1.37K Buy
52
+15
+41% +$447 ﹤0.01% 2435
2025
Q2 		$981 Buy
37
+8
+28% +$211 ﹤0.01% 2420
2025
Q1 		$700 Sell
29
-6
-17% -$190 ﹤0.01% 2604
2024
Q4 		$1.41K Buy
35
+34
+3,400% +$1.94K ﹤0.01% 2308
2024
Q3 		$63 Hold
1
– – ﹤0.01% 2572
2024
Q2 		$53 Hold
1
– – ﹤0.01% 1556
2024
Q1 		$82 Buy
+1
New +$44 ﹤0.01% 2454

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

CoreCap Advisors's VKTX Position: Q2 2026 in Review

CoreCap Advisors held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 102 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

CoreCap Advisors first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • CoreCap Advisors held 102 shares of Viking Therapeutics worth $3.98K as of Q2 2026.
  • CoreCap Advisors left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2346 holding.
  • CoreCap Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.